First-In-Human High-Cumulative-Dose Mesenchymal Stem Cell therapy in Multiple Myeloma: A Case Report - Abstract
Multiple myeloma (MM) is a highly malignant cancer characterized by the proliferation and accumulation of monoclonal plasma cells in the bone marrow along with end-organ damage due to the underlying disorder. Despite the remarkable progress in the treatment of MM with the availability of novel agents and hematopoietic cell transplantations (HCTs), an overwhelming majority of patients relapse and the disease is generally considered incurable. Here we report a case of a 57-year old male with relapsed MM previously treated with standard of care therapies including high-dose chemotherapy, radiotherapy, and autologous HCT. Based on our previous success with mesenchymal stem cell (MSC)-based therapy and its favorable safety profile, allogeneic MSC infusions were offered as a treatment option. A daily dose of 5.0 × 108 MSCs was slowly administered intravenously for
about one and a half hours to the patient for ten consecutive days. Three months after the treatment, his laboratory results had returned to within normal ranges and MRI showed complete resolution of the lesions. There were no significant adverse effects after administration of MSCs during the course of treatment and follow-up. The patient has since been cancer-free and no longer suffers from osteoporosis, which is usually a life-long complication for patients with MM. This first-in-human study showed that a high cumulative dose of MSCs is a safe and curative treatment for MM.